The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
A strategy to reduce cardiovascular disease by more than 80%
Open accessAbstract
Objectives To determine the combination of drugs and vitamins, and their doses, for use in a single daily pill to achieve a large effect in preventing cardiovascular disease with minimal adverse effects. The strategy was to simultaneously reduce four cardiovascular risk factors (low density lipoprotein cholesterol, blood pressure, serum homocysteine, and platelet function) regardless of pretreatment levels. Design We quantified the efficacy and adverse effects of the proposed formulation from published meta-analyses of randomised trials and cohort studies and a meta-analysis of 15 trials of low dose (50-125 mg/day) aspirin. Outcome measures Proportional reduction in ischaemic heart disease (IHD) events and strokes; life years gained; and prevalence of adverse effects. Results The formulation which met our objectives was: a statin (for example, atorvastatin (daily dose 10 mg) or simvastatin (40 mg)); three blood pressure lowering drugs (for example, a thiazide, a β blocker, and an angiotensin converting enzyme inhibitor), each at half standard dose; folic acid (0.8 mg); and aspirin (75 mg). We estimate that the combination (which we call the Polypill) reduces IHD events by 88% (95% confidence interval 84% to 91%) and stroke by 80% (71% to 87%). One third of people taking this pill from age 55 would benefit, gaining on average about 11 years of life free from an IHD event or stroke. Summing the adverse effects of the components observed in randomised trials shows that the Polypill would cause symptoms in 8-15% of people (depending on the precise formulation). Conclusion The Polypill strategy could largely prevent heart attacks and stroke if taken by everyone aged 55 and older and everyone with existing cardiovascular disease. It would be acceptably safe and with widespread use would have a greater impact on the prevention of disease in the Western world than any other single intervention.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Zhang, Q., Wang, C., Zheng, M., Li, Y., Li, J., Zhang, L., Shang, X., & Yan, C. (2015) · Cerebrovascular Diseases · doi:10.1159/000369778 · Cited by 11,533
Sacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., Brown, L., Warnica, J. W., Arnold, J. M. O., Wun, C.-C., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351401 · Cited by 7,439
Collaboration, A. T. (2002) · BMJ · doi:10.1136/bmj.324.7329.71 · Cited by 6,943
Blood pressure, stroke, and coronary heart disease
Collins, R., Peto, R., MacMahon, S., Godwin, J., Qizilbash, N., Collins, R., MacMahon, S., Hebert, P., Eberlein, K. A., Taylor, J. O., et al. (1990) · The Lancet · doi:10.1016/0140-6736(90)90944-z · Cited by 4,491
Altman, R., Carreras, L., Díaz, R. S., Figueroa, E. B., Paolasso, E., Parodi, J. C., Cade, J. F., Donnan, G. A., Eadie, M. J., Gavaghan, T. P., et al. (1994) · Cited by 3,322
Sleight, R. B., Sleight, P., Parish, S., Appleby, P. N., Collins, R., & Baigent, C. (1988) · PubMed · Cited by 2,868
(1958) · Journal of the American Pharmaceutical Association (Scientific ed.) · doi:10.1002/jps.3030470133 · Cited by 2,489
Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis
Wald, D. S., Law, M., & Morris, J. K. (2002) · BMJ · doi:10.1136/bmj.325.7374.1202 · Cited by 1,946
Self-citationLaw, M. R., Wald, N. J., & Rudnicka, A. R. (2003) · BMJ · doi:10.1136/bmj.326.7404.1423 · Cited by 1,720
Self-citationLaw, M. R., Wald, N. J., Morris, J. K., & Jordan, R. E. (2003) · BMJ · doi:10.1136/bmj.326.7404.1427 · Cited by 1,232
Self-citationLaw, M. R., Wald, N. J., & Thompson, S. G. (1994) · BMJ · doi:10.1136/bmj.308.6925.367 · Cited by 1,210
Self-citationThe way I see it: House officers need formal career development
Connor, A. (2002) · BMJ · doi:10.1136/bmj.324.7336.s71 · Cited by 1,143
Lowering blood homocysteine with folic acid based supplements: meta-analysis of randomised trials
Collaboration, H. L. T. (1998) · BMJ · doi:10.1136/bmj.316.7135.894 · Cited by 1,084
Decreased Rate of Coronary Restenosis after Lowering of Plasma Homocysteine Levels
Schnyder, G., Roffi, M., Pin, R., Flammer, Y., Lange, H., Eberli, F. R., Meier, B., Turi, Z. G., & Hess, O. M. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011364 · Cited by 532
Post-stroke antihypertensive treatment study. A preliminary result.
Pats, & Collaborating (1995) · Chinese Medical Journal · Cited by 467
When can a risk factor be used as a worthwhile screening test?
Wald, N. J., Hackshaw, A. K., & Frost, C. D. (1999) · BMJ · doi:10.1136/bmj.319.7224.1562 · Cited by 341
Self-citationLowering blood pressure to prevent myocardial infarction and stroke: a new preventive strategy
Law, M., Wald, N., & Morris, J. (2003) · Health Technology Assessment · doi:10.3310/hta7310 · Cited by 327
Self-citationRisk factor thresholds: their existence under scrutiny
Law, M. R., & Wald, N. J. (2002) · BMJ · doi:10.1136/bmj.324.7353.1570 · Cited by 268
Self-citationApolipoproteins and ischaemic heart disease: implications for screening
Wald, N., Watt, H., Bailey, A., Johnson, M., Ledue, T. B., & Haddow, J. (1994) · The Lancet · doi:10.1016/s0140-6736(94)90814-1 · Cited by 241
Self-citationThe Underlying Risk of Death After Myocardial Infarction in the Absence of Treatment
Law, M. R., Watt, H. C., & Wald, N. J. (2002) · Archives of Internal Medicine · doi:10.1001/archinte.162.21.2405 · Cited by 216
Self-citationRandomized Trial of Folic Acid Supplementation and Serum Homocysteine Levels
Wald, D. S., Bishop, L., Wald, N. J., Law, M., Hennessy, E., Weir, D., McPartlin, J., & Scott, J. (2001) · Archives of Internal Medicine · doi:10.1001/archinte.161.5.695 · Cited by 200
Self-citationCollaboration, H. L. T. (1998) · PubMed Central · Cited by 181
Post-stroke antihypertensive treatment study. A preliminary result.
(1995) · PubMed · Cited by 170
Willerson, J. T. (1996) · Circulation · doi:10.1161/01.cir.94.12.3054 · Cited by 84
Decreased rate of coronary restenosis after lowering of plasma homocysteine levels
Schnyder, G., Roffi, M., Pin, R., & Flammer, Y. (2002) · ACC Current Journal Review · doi:10.1016/s1062-1458(02)00658-x · Cited by 71
Cited by
Yusuf, S., Hawken, S., Ôunpuu, S., Dans, T., Avezum, A., Lanas, F., McQueen, M., Budaj, A., Pais, P., Varigos, J., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17018-9 · Cited by 12,026
Zhang, Q., Wang, C., Zheng, M., Li, Y., Li, J., Zhang, L., Shang, X., & Yan, C. (2015) · Cerebrovascular Diseases · doi:10.1159/000369778 · Cited by 11,533
European Guidelines on cardiovascular disease prevention in clinical practice (version 2012)
Authors/Task Force Members:, Perk, J., De Backer, G., Gohlke, H., Graham, I., Reiner, Ž., Verschuren, M., Albus, C., Benlian, P., Boysen, G., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs092 · Cited by 8,490
2016 European Guidelines on cardiovascular disease prevention in clinical practice
Piepoli, M. F., Hoes, A. W., Agewall, S., Albus, C., Brotons, C., Catapano, A. L., Cooney, M.-T., Corrà, U., Cosyns, B., Deaton, C., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw106 · Cited by 6,457
Mancia, G., De Backer, G., Dominiczak, A., Cifkova, R., Fagard, R., Germano, G., Grassi, G., Heagerty, A. M., Kjeldsen, S. E., Laurent, S., et al. (2007) · Journal of Hypertension · doi:10.1097/hjh.0b013e3281fc975a · Cited by 5,824
Metadata
- Authors
- Wald, N. J., & Law, M. R.
- Venue
- BMJ
- Publisher
- BMJ
- Published
- 2003-06-25
- Volume
- 326
- Issue
- 7404
- Pages
- 1419
- ISSN
- 0007-1447 (ISSN-L)
- 0959-8138
- 1468-5833
- OpenAlex
- W2163207768
- Cited by
- 1,568
- References
- 31
- FWCI
- 103.73
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.